Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.
Van den Bosch
F
F
Department of Rheumatology, University Hospital, Gent, Belgium. f.vandenbosch@pi.be
Baeten
D
D
Kruithof
E
E
De Keyser
F
F
Mielants
H
H
Veys
E M
EM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D009369:Neoplasms / Q000276:immunology; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D025242:Spondylarthropathies / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab